Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03408483 · ClinicalTrials.gov registry record · Phase 2
Quadratus Lumborum Block Versus Control for Total Hip Arthroplasty
A Phase 2 study of Total Hip Arthroplasty, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT03408483 is a Phase 2 study of Total Hip Arthroplasty that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 80 participants, below the 138-participant average among 12 other Total Hip Arthroplasty trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03408483, a Phase 2 study of Total Hip Arthroplasty, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Peripheral nerve blocks for joint and extremity surgeries have long been proven to provide effective post-operative analgesia. Of these surgeries, total hip arthroplasty (THA) remains one of the most common orthopedic procedures in the United States with approximately 300,000 operations performed annually. At our institution, post-operative analgesia in these patients is primarily provided through parenteral and oral opioid medications. Quadratus lumborum blocks (QLB) have been described and implemented for various surgical procedures including caesarean and laparoscopic ovarian surgery. Recently, there has been increasing interest in the efficacy of quadratus lumborum blocks for THA. Currently, case reports have established a precedent regarding the efficacy of the QLB for THA in providing superior analgesia and decreasing visual analog pain scores (VAS), but randomized trials are still lacking. The goal of this study is to compare pain scores (VAS), opioid consumption, physical therapy scores, and patient and surgeon satisfaction in patients that receive QLB versus no peripheral nerve blockade in patients undergoing THA. The results of this study have the potential to change standard of care for patients undergoing THA.
Conditions Studied
Interventions
- DRUG Standard of Care
- DRUG Quadratus Lumborum Block (QLB)
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2020-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03408483
The ClinicalTrials.gov registry entry for NCT03408483 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 138-participant average among 12 other Total Hip Arthroplasty trials with a reported enrollment target (42% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Total Hip Arthroplasty appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT03408483 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT03408483 about?
NCT03408483 is a clinical study titled "Quadratus Lumborum Block Versus Control for Total Hip Arthroplasty". Peripheral nerve blocks for joint and extremity surgeries have long been proven to provide effective post-operative analgesia. Of these surgeries, total hip arthroplasty (THA) remains one of the most common orthopedic procedures in the United States with approximately 300,000 operations performed an...
What is the current status of trial NCT03408483?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2018-04-01. Estimated completion is 2020-08-22.
What conditions does trial NCT03408483 study?
This clinical trial studies the following conditions: Total Hip Arthroplasty.
What interventions are being tested in trial NCT03408483?
The interventions under investigation include: Standard of Care (DRUG), Quadratus Lumborum Block (QLB) (DRUG).
Who is sponsoring clinical trial NCT03408483?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03408483 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Total Hip Arthroplasty
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study
RECRUITING · NA
-
Methadone in THA for Post-op Pain and Opioid Reduction
RECRUITING · Phase 3
-
Patient Utilization of Opioid Destruction Bags in the Post-op Period
ACTIVE NOT RECRUITING · NA
-
Strength and Function Following Total Hip Arthroplasty
COMPLETED · NA
-
Continuum™ Metal Bearing System in Total Hip Arthroplasty
COMPLETED
-
Total Hip Arthroplasty (THA) Lumbar Plexus Verses Periarticular
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.